TransCode Therapeutics Completes Phase 1a Trial of TTX-MC138, Advances to Phase 2 Evaluation

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has announced the completion of its Phase 1a clinical trial for TTX-MC138, an investigational inhibitor of microRNA-10b, achieving its primary safety endpoint and establishing a recommended Phase 2 dose. The trial involved sixteen patients who were treated with the therapeutic candidate, with no significant safety events or dose-limiting toxicities observed during the study period. This favorable safety profile represents a critical milestone for the company's RNA therapeutic platform and provides strong support for advancing the treatment into larger clinical trials.

The clinical results demonstrated that 44% of patients achieved stable disease lasting four months or longer, indicating potential therapeutic benefit beyond safety considerations. The durability of response observed in these patients, combined with pharmacodynamic data collected during the trial, provides compelling evidence for the continued development of TTX-MC138. These findings are particularly significant given that TTX-MC138 targets microRNA-10b, a well-documented biomarker of metastasis that plays a crucial role in cancer progression and spread throughout the body.

Based on these positive results, TransCode Therapeutics plans to advance TTX-MC138 into a Phase 2a trial to further assess efficacy across multiple metastatic cancer indications. The company's proprietary TTX nanoparticle platform, which forms the foundation of their RNA therapeutic approach, has demonstrated its capability to effectively deliver therapeutic RNA to target cells. This technological advancement addresses one of the key challenges in RNA-based cancer treatments, potentially unlocking access to novel genetic targets relevant to treating various cancers.

The successful completion of this Phase 1a trial marks an important step forward in the development of RNA-based cancer therapeutics. The company's newsroom at https://ibn.fm/RNAZ provides additional information about their ongoing research and development efforts. The broader implications of this advancement extend beyond TTX-MC138 specifically, as it demonstrates the viability of targeting microRNA-10b as a therapeutic strategy for metastatic cancers, potentially opening new treatment avenues for patients with advanced disease who have limited options.